Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc. has demonstrated strong financial performance, highlighted by a record increase in Signatera MRD volumes, with a quarterly rise of 21,500 tests, translating to a remarkable 54% year-over-year growth. The company is positioned for further revenue growth, particularly through the expansion of reimbursement coverage in oncology, which is expected to enhance average selling prices and improve gross margins. Additionally, Natera's recent quarterly results showed an approximate revenue beat of $80 million, coupled with a substantial increase of $160 million in its revenue guidance for 2025, indicating a robust upward trajectory for the company's financial outlook.

Bears say

Natera Inc. is facing potential margin erosion due to anticipated reductions in in-network pricing as more commercial payors begin to offer coverage and as its target market expands to include average risk patients. The company is also vulnerable to negative impacts from regulatory setbacks, reimbursement issues, or delays in product launches, which could adversely affect its financial performance and stock movement. Additionally, the firm may encounter challenges in expanding into international markets, particularly if compelling data and effective reimbursement strategies are not established.

Natera (NTRA) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 14 analysts, Natera (NTRA) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $259.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $259.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.